Swedish weight-loss drug Mounjaro tops sales, impacting optics sector
När ett läkemedel blir en samhällsförändring
Mounjaro has become Sweden’s best-selling medication, surpassing two billion kronor in September sales according to E-hälsomyndigheten. Patients pay 50,000–60,000 kronor annually out-of-pocket. Kairos Future data indicates seven percent of Swedes aged 16–74 have used Ozempic or similar weight-loss drugs. The EU approved the first oral weight-loss tablet this summer, while generic versions are available in India and Canada. PwC reports US households using these medications increased clothing purchases by nearly ten percent after six months. For the optical industry, EMA notes semaglutide can rarely cause NAION, a vision-threatening condition affecting up to one in 10,000 users. Additionally, changing body image may drive demand for new eyewear, though market impact depends on future pricing and studies.
Source:Optik (Sweden) · optik.optikbranschen.se